Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.39.

EBIT: As of FY2026 Q1, the actual value is USD -19.41 M.

Segment Revenue

Contineum Therapeutics, Inc. recognized no revenue for the three months ended March 31, 2026, and March 31, 2025, as it has no products approved for sale and has not yet generated any revenue from product sales.

Operational Metrics

• Net Loss: Contineum Therapeutics, Inc. reported a net loss of - $14.456 million for the three months ended March 31, 2026, compared to a net loss of - $15.990 million for the three months ended March 31, 2025.
• Total Operating Expenses: Total operating expenses were $16.904 million for the three months ended March 31, 2026, a decrease of - $1.206 million from $18.110 million for the same period in 2025.
• Research and Development (R&D) Expenses: R&D expenses decreased by - $2.1 million, from $13.712 million for the three months ended March 31, 2025, to $11.648 million for the three months ended March 31, 2026. This decrease was primarily due to a - $2.5 million reduction in contract research organization costs, including a - $2.3 million decrease related to the completed VISTA Phase 2 clinical trial for PIPE-307, a - $1.4 million decrease from the completed Phase 1b PET trial for PIPE-791, and a - $0.5 million decrease from the Phase 1b trial for PIPE-791 for chronic pain. These reductions were partially offset by a $1.7 million increase in costs for the Phase 2 trial of PIPE-791 for idiopathic pulmonary fibrosis (IPF). Additionally, there was a - $1.1 million decrease in toxicology study expenses, mainly for PIPE-791 and CTX-343, partially offset by a $0.8 million increase in personnel-related expenses, a $0.6 million increase in noncash stock-based compensation, and a $0.1 million increase in facilities costs.
  • R&D Expenses by Program (Three Months Ended March 31, in thousands):
    • PIPE-791: $6.051 million in 2026 vs. $5.554 million in 2025.
    • PIPE-307: $0.251 million in 2026 vs. $2.615 million in 2025.
    • CTX-343: $0.273 million in 2026 vs. $1.378 million in 2025.
    • Discovery programs: $1.426 million in 2026 vs. $1.382 million in 2025.
    • Unallocated internal costs: $3.647 million in 2026 vs. $2.783 million in 2025.
• General and Administrative (G&A) Expenses: G&A expenses increased by $0.9 million, from $4.398 million for the three months ended March 31, 2025, to $5.256 million for the three months ended March 31, 2026. This increase was primarily due to a $0.6 million increase in noncash stock-based compensation and a $0.2 million increase in personnel-related expenses.
• Loss from Operations: Loss from operations was - $16.904 million for the three months ended March 31, 2026, compared to - $18.110 million for the same period in 2025.
• Interest Income: Interest income increased by $0.2 million, from $2.250 million for the three months ended March 31, 2025, to $2.505 million for the three months ended March 31, 2026, due to an increase in funds invested in marketable securities.

Cash Flow

• Net Cash Used in Operating Activities: Net cash used in operating activities was - $16.266 million for the three months ended March 31, 2026, primarily due to a net loss of - $14.5 million and a - $5.9 million change in operating assets and liabilities, partially offset by $4.1 million in noncash charges. For the same period in 2025, net cash used in operating activities was - $14.412 million.
• Net Cash Used in Investing Activities: Net cash used in investing activities was - $39.308 million for the three months ended March 31, 2026, mainly from $97.117 million in purchases of marketable securities and - $0.312 million for property and equipment, partially offset by $58.121 million from sales and maturities of marketable securities. In contrast, net cash provided by investing activities was $14.915 million for the three months ended March 31, 2025.
• Net Cash Provided by Financing Activities: Net cash provided by financing activities was $0.129 million for the three months ended March 31, 2026, primarily from $0.198 million in proceeds from stock option exercises, partially offset by - $0.069 million in payments of deferred offering costs. For the same period in 2025, net cash provided by financing activities was $0.024 million.

Unique Metrics

• Cash, Cash Equivalents, and Marketable Securities: As of March 31, 2026, Contineum Therapeutics, Inc. had cash, cash equivalents, and marketable securities totaling $246.3 million.
• Accumulated Deficit: As of March 31, 2026, the accumulated deficit was - $191.8 million.

Future Outlook and Strategy

Contineum Therapeutics, Inc. expects its existing cash, cash equivalents, and marketable securities to support operations for at least the next 12 months from the report’s issuance date. The company anticipates a significant increase in operating expenses as it develops drug candidates, conducts clinical trials, seeks regulatory approvals, expands operations, and maintains its intellectual property. Future financing is expected through various channels, including equity and debt financings, or commercial arrangements like collaborations and licensing agreements.